Grants and Contributions:
Title:
Determination of polymer disposition and safety after drug product administration
Agreement Number:
979716
Agreement Value:
$700,000.00
Agreement Date:
Sep 1, 2021 - Dec 15, 2023
Description:
This project will determine the safety, metabolism and clearance of the novel coating, in particular the polymer component, of the firm's extended-release technology platform through in vivo studies to identify the mode and rate of elimination of the coating from the body after administration.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Victoria, British Columbia, CA V8R 5G4
Reference Number:
172-2021-2022-Q3-979716
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
818717308
Recipient Type:
For-profit organization
Recipient's Legal Name:
Eupraxia Pharmaceuticals Inc.
Federal Riding Name:
Victoria
Federal Riding Number:
59041
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710